Circulating soluble CD36 as a novel biomarker for progression and prognosis of HBV-related liver diseases

Circulating soluble CD36 as a novel biomarker for progression and prognosis of HBV-related liver diseases

BackgroundOur previous study suggested CD36 may be a positive regulator of hepatitis B virus (HBV) replication in vitro. Therefore, the present study aimed to investigate whether circulating soluble CD36 (sCD36) could serve as a diagnostic and prognostic biomarker for HBV-related liver diseases base...

Full description

Bibliographic Details
Main Authors:	Chunxian Cai, Anhua Xiao, Xiaoqing Luo, Enze Zheng, Yiyu Li, Yu Lei, Shan Zhong, Yaxi Chen, Ping Yang, Zhurong Tang, Zhi Zhou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-11-01
Series:	Frontiers in Microbiology
Subjects:	sCD36 biomarker HBV-related liver diseases cirrhosis liver failure
Online Access:	https://www.frontiersin.org/articles/10.3389/fmicb.2022.1039614/full

Similar Items

The polymorphism analysis for CD36 among platelet donors
by: Qilu Lyu, et al.
Published: (2024-04-01)

Impact of the interaction between the polymorphisms and hypermethylation of the CD36 gene on a new biomarker of type 2 diabetes mellitus: circulating soluble CD36 (sCD36) in Senegalese females
by: Maïmouna Touré, et al.
Published: (2022-08-01)

Soluble Receptors Affecting Stroke Outcomes: Potential Biomarkers and Therapeutic Tools
by: Ayon Bhattacharya, et al.
Published: (2021-01-01)

HBV Infection and Host Interactions: The Role in Viral Persistence and Oncogenesis
by: Riccardo Nevola, et al.
Published: (2023-04-01)

PLASMA LEVEL OF SOLUBLE CD30 IN PEDIATRIC LIVING-DONOR LIVER TRANSPLANT PATIENT
by: O. P. Shevchenko, et al.
Published: (2011-12-01)

The Circulating Fatty Acid Transporter Soluble CD36 Is Not Associated with Carotid Atherosclerosis in Subjects with Type 1 and Type 2 Diabetes Mellitus
by: Esmeralda Castelblanco, et al.
Published: (2020-06-01)

Adaptive Subsets Limit the Anti-Tumoral NK-Cell Activity in Hepatocellular Carcinoma
by: Charlotte Rennert, et al.
Published: (2021-06-01)

Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure
by: Marlene Christina Nielsen, et al.
Published: (2020-05-01)

The Role of Antiviral Prophylaxis in Preventing HBV and HDV Recurrence in the Setting of Liver Transplantation
by: Sara Battistella, et al.
Published: (2023-04-01)

The role of antiviral therapy in the management of patients with liver cirrhosis associated with chronic HBV and HCV infection
by: D. V. Garbuzenko
Published: (2021-11-01)

Illuminating HBV with multi-scale modeling
by: Shawn A. Means, et al.
Published: (2023-02-01)

Editorial: The current challenges underlying hepatitis D virus infection
by: Romina Salpini, et al.
Published: (2024-01-01)

HBsAg level defines different clinical phenotypes of HBeAg(−) chronic HBV infection related to HBV polymerase-specific CD8+ cell response quality
by: Julia Peña-Asensio, et al.
Published: (2024-03-01)

Evaluation of the HBV liver reservoir with fine needle aspirates
by: Barbara Testoni, et al.
Published: (2023-10-01)

Single-cell RNA transcriptomics reveals differences in the immune status of alcoholic and hepatitis B virus-related liver cirrhosis
by: Pengpeng Zhang, et al.
Published: (2023-02-01)

The Anti-TNF-α Antibody Infliximab Inhibits the Expression of Fat-Transporter-Protein FAT/CD36 in a Selective Hepatic-Radiation Mouse Model
by: Gesa Martius, et al.
Published: (2015-03-01)

Study on pathological and clinical characteristics of chronic HBV infected patients with HBsAg positive, HBV DNA negative, HBeAg negative
by: Zhan Zeng, et al.
Published: (2023-01-01)

Soluble CD27 and MIF as possible serum biomarkers of vitiligo activity in Egyptian patients in Sharkia Governorate
by: Mohamed Ibrahim El-Ghareeb, et al.
Published: (2019-12-01)

Validation of Hepatocellular Carcinoma Risk Prediction Models in Patients with Hepatitis B-Related Cirrhosis
by: Cheng R, et al.
Published: (2022-09-01)

A retrospective case-series of influence of chronic hepatitis B on synchronous liver metastasis of colorectal cancer
by: Lin Zhu, et al.
Published: (2023-02-01)

In Vivo Bioluminescence Imaging of HBV Replicating Hepatocytes Allows for the Monitoring of Anti-Viral Immunity
by: Katrin Manske, et al.
Published: (2021-11-01)

Patients with SARS-CoV-2 and HBV co-infection are at risk of greater liver injury
by: Yong Lin, et al.
Published: (2021-07-01)

Prevalence and clinical correlates of insomnia symptoms and their association with quality of life in Chinese patients with HBV-related liver disease
by: Jing Zhao, et al.
Published: (2021-03-01)

Impact of Liver Fibrosis Severity on Oncological Prognosis in Hepatocellular Carcinoma
by: Koya Yasukawa, et al.
Published: (2023-10-01)

CD73, a significant protein in liver diseases
by: Huilian Shi, et al.
Published: (2023-04-01)

Complement regulatory proteins: Candidate biomarkers in differentiating tuberculosis pleural effusion
by: Huan Tang, et al.
Published: (2023-02-01)

Study on liver histopathology of chronic HBV infected patients with different normal ALT values
by: Zhan Zeng, et al.
Published: (2022-11-01)

The Origin of Capsid-Derived Immune Complexes and Their Impact on HBV-Induced Liver Diseases
by: Xiaonan Zhang, et al.
Published: (2022-12-01)

Frequency and molecular basis of CD36 deficiency among platelet donors in Kunming, China
by: Qilu Lyu, et al.
Published: (2023-12-01)

Gender differences in demographic and clinical characteristics in patients with HBV-related liver diseases in China
by: Mei Liu, et al.
Published: (2022-08-01)

Discontinuation of Passive Immunization Is Safe after Liver Transplantation for Combined HBV/HDV Infection
by: Ramin Raul Ossami Saidy, et al.
Published: (2021-05-01)

LIVER TRANSPLANTATION AND HBV INFECTION
by: O. I. Andreytseva, et al.
Published: (2009-06-01)

The Combination of Nucleotide Analog Therapy and Steroid Pulse Therapy for Acute HBV Infection Effectively Promotes HBV Clearance
by: Takeshi Goya, et al.
Published: (2021-12-01)

Prognostic value of plasma level of superoxide dismutase in HBV-related acute-on-chronic liver failure
by: Naijuan Yao, et al.
Published: (2022-06-01)

Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis
by: Miwa Kawanaka, et al.
Published: (2023-05-01)

NAFLD and HBV interplay - related mechanisms underlying liver disease progression
by: Evanthia Tourkochristou, et al.
Published: (2022-12-01)

Obstacles and opportunities in the prevention and treatment of HBV-related hepatocellular carcinoma
by: Yong Liao
Published: (2020-09-01)

Circulating Cytokines Reflect the Etiology-Specific Immune Environment in Cirrhosis and HCC
by: Boris J. B. Beudeker, et al.
Published: (2022-10-01)

Circulating Receptor-Interacting Protein Kinase 3 Are Increased in HBV Patients With Acute-on-Chronic Liver Failure and Are Associated With Clinical Outcome
by: Liwen Chen, et al.
Published: (2020-06-01)

Single-cell landscape of immune cells during the progression from HBV infection to HBV cirrhosis and HBV-associated hepatocellular carcinoma
by: Qingquan Bai, et al.
Published: (2023-12-01)